METHODS: We used shRNAs to knockdown the expression of MCAM in the lytic PC-3M-Pro4Luc2_dTomato and in the blastic C4-2B_dTomato PCa cell lines. We validated the knockdown at protein level and tested the effect with functional assays such as migration, proliferation. RT-qPCR was used to test MCAM knockdown on EMT markers. The effect of the knockdown on the maintenance of cancer stem/progenitor-like cells was measured by ALDEFLUOR.
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RESULTS: MCAM knockdown reduced proliferation in PC-3M-Pro4Luc2_dTomato PCa cells and resulted in increased ECadherin expression. Conversely, no effect on proliferation was measured on C4-2B_dTomato cells. It has been described that metastatic human PCa cells target the hematopoietic stem cell (HSC) niche in the bone marrow at the level of an »endosteal/ osteoblast« niche and a »vascular/perivascular« niche. We set-up an in vitro model of »osteoblast niche« to study the behavior of prostate cancer cells upon co-culture with osteoblasts and to measure the resulting effects on cancer stem/progenitor-like markers. We found that MCAM is required for the osteoblast-mediated induction of ALDH activity on PCa cells and MCAM knockdown prevented the increase in the size of the ALDH high subpopulation in PC-3M-Pro4-Luc2_dTomato, mediated by human osteoblasts. (PC) , resulting in ERG overexpression. In Western populations, approximately 50% of PCs express fusion products; however, our previous study showed that ERG expression was less frequent in a cohort of Japanese patients with localized PC (15/92, 16.3%). The association between ERG overexpression and the clinical behavior of PC is controversial. SPINK1 overexpression is noted in approximately 10% of patients with localized PC, mutually exclusive of ERG overexpression. Although the association of SPINK1 overexpression with an aggressive PC phenotype has been reported, its prognostic significance is unclear. PC is occasionally diagnosed at autopsy and during cystoprostatectomy for bladder cancer; most of these cases are thought to represent the latent phase of the tumor. Thus, assessment of ERG and SPINK1 expression in latent, incidental, and metastatic PC (the most aggressive form) may be useful in evaluating the association between ERG and SPINK1 expression and the biological aggressiveness of the tumor.
METHODS: In total, 151 autopsies among institutional autopsy records from 2009 to 2015 and 84 cystoprostatectomy specimens were included. Each prostate gland was fixed and sliced into step sections. Ninety-eight prostate biopsy specimens from a cohort of patients who received an initial diagnosis of metastatic PC between 2003 and 2012 were investigated. ERG and SPINK1 expression was assessed by immunohistochemistry and the expression patterns were compared to clinicopathological parameters.
RESULTS: PC was identified in 53/151 autopsies and 20/84 cystoprostatectomy specimens. ERG and SPINK1 expression patterns were not significantly different [4/73 (5.5%) and 5/73 (8.3%) in the latent/incidental PC cohort and 14/98 (14.3%) and 12/98 (12.2%) in the metastatic PC cohort, respectively]. SPINK1 was almost exclusively expressed in ERG-negative tumors, except in one case. In the metastatic PC cohort, ERG and SPINK1 expression patterns were not associated with age, prostate-specific antigen level, and the Gleason score. SPINK1 expression was significantly associated with a shorter time to castration-resistant PC (P¼0.0151), although ERG expression was not associated with clinical outcomes.
CONCLUSIONS: ERG and SPINK1 expression was not significantly different between latent/incidental PC and metastatic PC. SPINK1 expression may be a predictor of a shorter response to androgen deprivation therapy in metastatic PC.
Source of Funding: none e596 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 
